基于患者特异性肺弹性推导新型影像生物标志物以表征肺癌SBRT患者COPD程度的可行性
本研究对13例根据GOLD 2017标准已知COPD诊断的肺癌患者行4DCT,用形变配准获得形变矢量场作为金标准,构建线性弹性生物力学模型迭代优化肺组织弹性分布,得到基于体素弹性的影像生物标志物YM1-3。与现行金标准RA950相比,YM1-3诊断准确率86% vs 71%、敏感度0.875 vs 0.5、AUROC 0.917 vs 0.875。作者认为肺组织弹性作为生物标志物可能为临床试验提供新终点并为COPD亚组提供靶向治疗。
要点
- 基于4DCT弹性建模得到的YM1-3诊断准确率86%、敏感度0.875、AUROC 0.917,均高于RA950的71%、0.5、0.875。
- 估计弹性代表金标准形变矢量场的准确率为90%。
- YM1-3既可作为肺病理生理的空间指标,也证明是优于RA950的诊断指标。
核心结论
- 结果提示肺组织弹性作为生物标志物可能为临床试验带来新终点,并为COPD亚组带来新的靶向治疗。
研究设计与样本
- 可行性研究,纳入13例根据GOLD 2017标准已知COPD诊断的肺癌患者,采集4DCT图像;以吸气末与呼气末形变配准得到的形变矢量场为金标准,从呼气末数据集构建密度引导初始弹性分布的线性弹性生物力学模型,迭代优化弹性估计。
关键影像表现/征象
- 估计弹性代表金标准形变矢量场的准确率为90%。
- 基于优化弹性分布推导的影像生物标志物YM1-3与现行金标准RA950进行比较。
诊断标准与关键数值
- YM1-3诊断准确率86%,敏感度0.875,AUROC 0.917。
- RA950诊断准确率71%,敏感度0.5,AUROC 0.875。
- COPD诊断依据GOLD 2017标准。
临床应用与阅片要点
- 作者认为肺组织弹性作为生物标志物可能为临床试验提供新终点并为COPD亚组提供新的靶向治疗。
- 从4DCT数据直接推导弹性信息是肺弹性成像的新方法。
- 本工作证明需要基于力学的生物标志物来表征肺病理生理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE:: Lung tissue elasticity is an effective spatial representation for Chronic Obstructive Pulmonary Disease phenotypes and pathophysiology. We investigated a novel imaging biomarker based on the voxel-by-voxel distribution of lung tissue elasticity. Our approach combines imaging and biomechanical modeling to characterize tissue elasticity.
METHODS:: We acquired 4DCT images for 13 lung cancer patients with known COPD diagnoses based on GOLD 2017 criteria. Deformation vector fields (DVFs) from the deformable registration of end-inhalation and end-exhalation breathing phases were taken to be the ground-truth. A linear elastic biomechanical model was assembled from end-exhalation datasets with a density-guided initial elasticity distribution. The elasticity estimation was formulated as an iterative process, where the elasticity was optimized based on its ability to reconstruct the ground-truth. An imaging biomarker (denoted YM1-3) derived from the optimized elasticity distribution, was compared with the current gold standard, RA950 using confusion matrix and area under the receiver operating characteristic (AUROC) curve analysis.
RESULTS:: The estimated elasticity had 90 % accuracy when representing the ground-truth DVFs. The YM1-3 biomarker had higher diagnostic accuracy (86% vs 71 %), higher sensitivity (0.875 vs 0.5), and a higher AUROC curve (0.917 vs 0.875) as compared to RA950. Along with acting as an effective spatial indicator of lung pathophysiology, the YM1-3 biomarker also proved to be a better indicator for diagnostic purposes than RA950.
CONCLUSIONS:: Overall, the results suggest that, as a biomarker, lung tissue elasticity will lead to new end points for clinical trials and new targeted treatment for COPD subgroups.
ADVANCES IN KNOWLEDGE:: The derivation of elasticity information directly from 4DCT imaging data is a novel method for performing lung elastography. The work demonstrates the need for a mechanics-based biomarker for representing lung pathophysiology.
引用
- Hasse K, Neylon J, Min Y, et al. Feasibility of deriving a novel imaging biomarker based on patient-specific lung elasticity for characterizing the degree of COPD in lung SBRT patients. Br J Radiol. 2018. PMID: 30281329. doi:10.1259/bjr.20180296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。